| Target | |
|---|---|
| Synonyms | CANN6; CB-R; CNR1; CB1A; CB1K5; CB1R; CNR |
| Description | Human CB1 full length protein membrane nanoparticles (MNPs) |
| Delivery | In Stock |
| Uniprot ID | P21554 |
| Expression Host | HEK293 |
| Protein Families | GPCR |
| Protein Pathways | Neuroactive ligand-receptor interaction |
| Molecular Weight | The human full length CB1 Protein has a MW of 52.7 kDa |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Storage & Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Background | The cannabinoids, principally delta-9-tetrahydrocannabinol and synthetic analogs, are psychoactive ingredients of marijuana. The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family, which inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two receptors have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. Multiple transcript variants encoding two different protein isoforms have been described for this gene. |
| Usage | Research use only |
Human CB1 full length protein-MNP
Price: 50 μg $1200.00 ; 100 μg $1600.00
Product Data
Images
Figure1. Elisa plates were pre-coated with 0.5μg/per well purified human CB1 full length membrane nanoparticles. Serial diluted anti-CB1 monoclonal antibody (DME100144) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CB1 monoclonal antibody binding with CB1 full length membrane nanoparticles is 439.6ng/ml.
Figure2. FACS analysis of CB1 MNPs
A. Negative Control 1: CB1 full length membrane nanoparticles samples were stained only with Goat anti-human lgG 488 secondary antibody.
B. Negative Control 2: Control membrane nanoparticles samples were stained with anti-CB1 antibody (BME100049) at 2μg/mL, followed by Goat anti-human IgG 488 secondary antibody.
C. Negative Control 3: CB1 full length membrane nanoparticles samples were stained with anti-CCR8 antibody (an irrelevant antibody) at 2μg/mL, followed by Goat anti-human IgG 488 secondary antibody.
D. CB1 full length membrane nanoparticles samples were stained with anti-CB1 antibody (BME100049) at 2μg/mL, followed by Goat anti-human IgG 488 secondary antibody.